Breaking News Instant updates and real-time market news.

PFE

Pfizer

$32.97

0.16 (0.49%)

08:02
06/19/17
06/19
08:02
06/19/17
08:02

Pfizer begins Phase 1 clinical trial to evaluate Group B Streptococcus vaccine

Pfizer Inc. announced that it has started a Phase 1 trial in healthy volunteers of PF-06760805, an investigational vaccine designed to help protect against Group B Streptococcus infection. In newborns, GBS manifests as sepsis, pneumonia, and meningitis, with potentially fatal outcomes for some, and long-lasting neurological damage in 46 to 50 percent of those infected. The trial is designed as a Phase 1/2 randomized, placebo-controlled, observer-blinded study in healthy adults 18 to 49 years of age with no history of a GBS infection, and will be conducted in the United States. Because of the urgent need to help protect newborns in low- and middle-income countries from this devastating condition, and the intent to make a successfully developed vaccine available globally as quickly as possible, Pfizer is pursuing a clinical development strategy in high-, middle- and low-income countries. In 2016, Pfizer received a grant from the Bill & Melinda Gates Foundation to conduct a Phase 1/2 clinical trial of Pfizer's vaccine candidate against GBS infection in South Africa, which has one of the highest invasive GBS disease incidences of 2.38 cases per 1,000 live births.

  • 02

    Aug

  • 27

    Aug

PFE Pfizer
$32.97

0.16 (0.49%)

05/16/17
05/16/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Pfizer (PFE) downgraded to Sell from Neutral at Citi with analyst Andrew Baum saying his concern over Pfizer's "rising risk to high price" Medicare Part D covered oncology drugs, namely Xtandi, Ibrance and Xalkori, has intensified. He also believes "major transaction risk" for Pfizer remains high. 2. MercadoLibre (MELI) downgraded to Neutral from Overweight at JPMorgan with analyst Andre Baggio citing valuation with the stock up 131% year-over-year. 3. Eli Lilly (LLY) downgraded to Buy from Conviction Buy at Goldman Sachs with analyst Jami Rubin citing strong year-to-date performance. The analyst maintained a Buy rating and $92 price target citing favorable long-term fundamentals with significant margin expansion. 4. Valero (VLO) downgraded to Neutral from Buy at Goldman Sachs with analyst Neil Mehta citing a more balanced risk/reward following the stock's outperformance. 5. NantKwest (NK) downgraded to Sell from Neutral at Citi with analyst Joel Beatty saying the company has a history of "significantly missing" its clinical trial timelines, and this is unlikely to change over the near-term. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
05/25/17
PIPR
05/25/17
NO CHANGE
PIPR
Piper calls AbbVie and Pfizer dividends 'compelling'
In a research note on large-cap Pharma, Piper Jaffray analyst Richard Purkiss calls the dividends of AbbVie (ABBV) and Pfizer (PFE) "compelling." These two dividends "stand out with an unusually compelling combination of high yield alongside a high growth outlook," Purkiss tells investors in a research note, citing his analysis. He reiterates Overweight ratings on both stocks.
06/06/17
WELS
06/06/17
NO CHANGE
WELS
Amazon may be the next threat to drug pricing, says Wells Fargo
After CNBC recently reported that Amazon (AMZN) is considering going into the prescription pharmacy business in the U.S., Wells Fargo surveyed nearly 2,900 U.S. adults and found that 54% of those polled said they would use or would probably use "Amazon Pharmacy." While the e-commerce giant has not confirmed its U.S. pharmacy interest, if it did enter the market analyst David Maris believes it could see fast adoption and "usher in a new age of price transparency." Maris also wonders if pharmacy "may be just the beginning" and if Amazon eyes the "even larger prize" of fully integrated digital healthcare. Publicly traded large-cap pharmaceuticals companies include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY). Publicly traded retail pharmacy operators include CVS Health (CVS), Walgreens (WBA), Fred's (FRED) and Rite Aid (RAD).
06/07/17
FBCO
06/07/17
NO CHANGE
Target $38
FBCO
Outperform
ASCO meeting highlights pressure on Pfizer cancer assets, says Credit Suisse
Credit Suisse analyst Vamil Divan said he came away from the ASCO meeting feeling like positive progress by competitors is increasing the pressure on Pfizer's (PFE) cancer assets, specifically pointing to positive data for Roche's (RHHBY) Alecensa, Johnson & Johnson's (JNJ) Zytiga and Eli Lilly's (LLY) abemaciclib. Additionally, competition in the immune-oncology and PARP spaces will make it more challenging for Pfizer to gain traction, added Divan. He keeps an Outperform rating on Pfizer, citing valuation and its dividend yield, but he has concerns about its upcoming patent expirations and growth products.

TODAY'S FREE FLY STORIES

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.